Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP58261.RA3Ve80nFVxExqA0TX2BZxrtJYJkWKTQ6FIuYcf0Pkl5c130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP58261.RA3Ve80nFVxExqA0TX2BZxrtJYJkWKTQ6FIuYcf0Pkl5c130_assertion type Assertion NP58261.RA3Ve80nFVxExqA0TX2BZxrtJYJkWKTQ6FIuYcf0Pkl5c130_head.
- NP58261.RA3Ve80nFVxExqA0TX2BZxrtJYJkWKTQ6FIuYcf0Pkl5c130_assertion description "[Although GLP-1 receptor (GLP-1R) agonists are under development for the treatment of diabetes, GLP-1 administration may increase blood pressure and heart rate in vivo.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP58261.RA3Ve80nFVxExqA0TX2BZxrtJYJkWKTQ6FIuYcf0Pkl5c130_provenance.
- NP58261.RA3Ve80nFVxExqA0TX2BZxrtJYJkWKTQ6FIuYcf0Pkl5c130_assertion evidence source_evidence_predicted NP58261.RA3Ve80nFVxExqA0TX2BZxrtJYJkWKTQ6FIuYcf0Pkl5c130_provenance.
- NP58261.RA3Ve80nFVxExqA0TX2BZxrtJYJkWKTQ6FIuYcf0Pkl5c130_assertion SIO_000772 12093887 NP58261.RA3Ve80nFVxExqA0TX2BZxrtJYJkWKTQ6FIuYcf0Pkl5c130_provenance.
- NP58261.RA3Ve80nFVxExqA0TX2BZxrtJYJkWKTQ6FIuYcf0Pkl5c130_assertion wasDerivedFrom rgd-2016 NP58261.RA3Ve80nFVxExqA0TX2BZxrtJYJkWKTQ6FIuYcf0Pkl5c130_provenance.
- NP58261.RA3Ve80nFVxExqA0TX2BZxrtJYJkWKTQ6FIuYcf0Pkl5c130_assertion wasGeneratedBy ECO_0000218 NP58261.RA3Ve80nFVxExqA0TX2BZxrtJYJkWKTQ6FIuYcf0Pkl5c130_provenance.